The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).Major outcomes in high-risk hypertensive patients randomised to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic. JAMA2002;23:2981-97.
2.
Neaton JD, Grimm RH Jr, Prineas RJ et al. Treatment of mild hypertension study: final results: Treatment of Mild Hypertension Study Research Group. JAMA1993;270:713-24.
3.
The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).Major cardiovascular events in hypertensive patients randomised to doxazosin vs. chlorthalidone . JAMA2000;283:1957-75.
4.
Collins R., Peto R., MacMahon S. et al. Blood pressure, stroke and coronary heart disease. Part 2, short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet1990;335:827-38.
5.
Neal B., MacMahon S., Chapman N for the Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Lancet2000;356:1955-64.overviews of ran
6.
Sever PS, Dahlof B., Poulter NR et al. Rationale, design, methods, and baseline demography of participants of the Anglo-S Scandinavian Cardiac Outcomes Trial. J Hypertens2002; 19:1139-47.
7.
Mann J., Julius S.The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial of cardiovascular events in hypertension. Rationale and design. Blood Press1998;7:176-83.
8.
Psaty BM, Heckbert SR, Koepsell TD et al. The risk of MI associated with antihypertensive drug therapies . JAMA1995; 274:620-5.
9.
Heart Outcomes Prevention (HOPE) Study Investigators.Effect of ramipril on cardiovascular and microvascular outIcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet2000;355:253-9.
10.
Williams B.The renin angiotensin system and cardiovascular disease: hope or hype?JRAAS2000;1:142-6.
11.
Poulter N., Williams B.Doxazosin for the management of hypertension: implications of the findings of the ALLHAT trial. Letter to the Editor. Am J Hypertens2001;14:1170-1.
12.
Chalmers J.All hats off to ALLHAT: a massive study with clear messages. J Hypertens2003;21:225-8.
13.
Fagard RHThe ALLHAT trial: strengths and limitations. J Hypertens2003;21:229-32.
14.
Kaplan NMThe meaning of ALLHAT. J Hypertens2003; 21:233-4.
15.
Multiple risk factor intervention trial research group - mortality rates after 10.5 years for participants in the multiple risk factor intervention trial. JAMA1990;263:1795-801.
16.
Brown MJ, Palmer CR, Castaigne A. et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium channel blocker of diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT) . Lancet2000;356:366-72.
17.
The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT).Major outcomes in moderately hypercholesterolemic, hypertensive patients randomised to pravastatin vs. usual care. JAMA2002;288:2998-3007.
